{"id":47440,"date":"2026-07-10T00:36:18","date_gmt":"2026-07-10T00:36:18","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/avance-clinical-to-showcase-asia-and-china-growth-strategy-at-bio-asia-taiwan-2026\/"},"modified":"2026-07-10T00:36:18","modified_gmt":"2026-07-10T00:36:18","slug":"avance-clinical-to-showcase-asia-and-china-growth-strategy-at-bio-asia-taiwan-2026","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/avance-clinical-to-showcase-asia-and-china-growth-strategy-at-bio-asia-taiwan-2026\/","title":{"rendered":"Avance Clinical to Showcase Asia and China Growth Strategy at BIO Asia\u2013Taiwan 2026"},"content":{"rendered":"
\n

ADELAIDE, Australia, July 10, 2026 (GLOBE NEWSWIRE) — Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced its participation in BIO Asia\u2013Taiwan 2026<\/strong>, taking place 15\u201319 July at the Taipei Nangang Exhibition Center (TaiNEX), Taipei. The event underscores Avance Clinical\u2019s continued investment in Asia and China, where sponsor demand for globally aligned, multi-regional clinical development continues to accelerate.<\/p>\n

Ben Edwards, Chief Operating Officer<\/strong> at Avance Clinical, said the company\u2019s presence at BIO Asia\u2013Taiwan reflects its growing engagement across the region. The company maintains established clinical operations in South Korea and Taiwan and has appointed Business Development Directors based in Shanghai and Beijing to deepen engagement with China\u2019s biotech innovation hubs. The move positions Avance Clinical for its next stage of growth in the market, ahead of establishing full operations, and reflects its commitment to supporting China-based sponsors with globally aligned, multi-regional delivery.<\/p>\n

\u201cAsia and China represent some of the most dynamic biotech ecosystems in the world, and our role is to help sponsors move through early development with speed and confidence, then scale seamlessly into multi-regional and global programs,\u201d said Edwards. \u201cWe are looking forward to being in Taipei to meet directly with our Taiwan and broader Asia-based clients, and to reinforce Avance Clinical\u2019s ongoing commitment to supporting biotech sponsors across the region. At BIO Asia\u2013Taiwan we will be sharing how our integrated model supports sponsors end-to-end, from first-in-human studies through to pivotal, multi-country delivery.\u201d<\/p>\n

Ben Edwards will attend BIO Asia\u2013Taiwan 2026 and present a session on end-to-end trial execution for biotech sponsors developing multi-regional programs.<\/p>\n

Jessica Han, Director Asia Operations <\/strong>at Avance Clinical, added that the region\u2019s momentum is reshaping how sponsors approach global development. \u201cBiotech sponsors across Asia and China are looking for a single CRO partner who can move quickly in-region while maintaining the regulatory rigour needed for global submissions,\u201d said Han. \u201cOur established operations in Korea and Taiwan, together with our Business Development Directors now based in Shanghai and Beijing, mean we can engage China-based sponsors directly and connect them into Australia\u2019s early-phase model and our North American later-phase capability, so programs can scale without losing continuity or quality.\u201d<\/p>\n

Supporting Fast, Globally Accepted Early-Phase Data<\/strong><\/p>\n

Many Asia-based and China-based biotechs are increasingly using Australia as the starting point for early-phase development before expanding regionally and globally. Avance Clinical\u2019s Australian model offers rapid ethics approvals, no requirement for an open IND, and accessing an Australian Government R&D tax rebate up to a 43.5% on eligible clinical trial costs. Data generated through this pathway is designed for global acceptance, including by the FDA, EMA, TGA and MHRA, giving sponsors a capital-efficient route into multi-regional trials spanning Asia, Australia, and the US.<\/p>\n

Meet Avance Clinical at BIO Asia\u2013Taiwan 2026<\/strong><\/p>\n

Sponsors and partners attending BIO Asia\u2013Taiwan 2026 are invited to meet with Avance Clinical\u2019s senior leadership, including Ben Edwards and members of the Asia Operations team, to discuss multi-regional trial strategy, early-phase development in Australia, and regional execution across Asia and China. Book a meeting<\/a> with us, noting \u2018BIO Asia\u2013Taiwan 2026\u2019 in the notes field.<\/p>\n

About Avance Clinical<\/strong><\/p>\n

Avance Clinical is a full-service, Australian-headquartered global Contract Research Organization, servicing international biotechs across North America, Europe, Asia Pacific and China. Specializing in early-phase and First-in-Human studies across more than 250 indications, as well as Oncology, Renal, Metabolic, and Central Nervous System trials, Avance Clinical has partnered with more than 700 emerging biotech companies to accelerate their programs to critical development milestones. Avance Clinical is the 2026 Frost & Sullivan Global Company of the Year in the Biotech CRO industry. To learn more, visit www.avancecro.com<\/a>.<\/p>\n

Find out more:<\/strong><\/p>\n

Media Contact
<\/strong>media@avancecro.com<\/a><\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

ADELAIDE, Australia, July 10, 2026 (GLOBE NEWSWIRE) — Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced its participation in BIO Asia\u2013Taiwan 2026, taking place 15\u201319 July at the Taipei Nangang Exhibition Center (TaiNEX), Taipei. The event underscores Avance Clinical\u2019s continued investment in Asia and China, where sponsor demand for globally […]<\/p>\n","protected":false},"author":2,"featured_media":47441,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/d962b5ae-4411-409e-b901-c81c838d1ad1","fifu_image_alt":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-47440","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t